Sequence-specific inhibition of gene expression in intact human skin by epicutaneous application of chimeric antisense oligodeoxynucleotides

Laboratory Investigation

Volumn 79, Issue 11, 1999, Pages 1415-1424

  Wingens, Miriam ^a   Pfundt, Rolph ^a   Van Vlijmen Willems, Ivonne M J J ^a   Van Hooijdonk, Candida A E M ^a   Van Erp, Piet E J ^a   Schalkwijk, Joost ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTISENSE OLIGODEOXYNUCLEOTIDE; CYTOKERATIN; ELAFIN; INVOLUCRIN; PHOSPHOROTHIOIC ACID; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR;

AMINO ACID SEQUENCE; ARTICLE; CHIMERA; CONTROLLED STUDY; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATINOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; SKIN; SKIN CULTURE;

ABSORPTION; ADENOSINE MONOPHOSPHATE; ADMINISTRATION, TOPICAL; BASE SEQUENCE; CHIMERA; GENE EXPRESSION; HUMANS; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDES, ANTISENSE; PROTEINASE INHIBITORY PROTEINS, SECRETORY; PROTEINS; SKIN; SKIN PHYSIOLOGY;

EID: 0032726353     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Alkemade JA, Molhuizen HO, Ponec M, Kempenaar JA, Zeeuwen PL, de Jongh GJ, van Vlijmen Willems IM, van Erp PE, van de Kerkhof PC, and Schalkwijk J (1994). SKALP/elafin is an inducible proteinase inhibitor in human epidermal keratinocytes. J Cell Sci 107:2335-2342.
2. Benimetskaya L, Tonkinson JL, Koziolkiewicz M, Karwowski B, Guga P, Zeltser R, Stec W, and Stein CA (1995). Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin is P-chirality independent. Nucleic Acids Res 23: 4239-4245.
3. Bennett CF (1998). Antisense oligonucleotides: Is the glass half full or half empty? Biochem Pharmacol 55:9-19.
4. Bennett CF, Chiang MY, Wilson Lingardo L, and Wyatt JR (1994). Sequence specific inhibition of human type II phospholipase A2 enzyme activity by phosphorothioate oligonucleotides. Nucleic Acids Res 22:3202-3209.
5. Bishop MR, Iversen PL, Bayever E, Sharp JG, Greiner TC, Copple BL, Ruddon R, Zon G, Spinolo J, Arneson M, Armitage JO, and Kessinger A (1996). Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J Clin Oncol 14:1320-1326.
6. Dean NM, McKay R, Miraglia L, Geiger T, Muller M, Fabbro D, and Bennett CF (1996). Antisense oligonucleotides as inhibitors of signal transduction: Development from research tools to therapeutic agents. Biochem Soc Trans 24:623-629.
7. De Water R, Willems LN, Van Muijen GN, Franken C, Fransen JA, Dijkman JH, and Kramps JA (1986). Ultrastructural localization of bronchial antileukoprotease in central and peripheral human airways by a gold-labeling technique using monoclonal antibodies. Am Rev Respir Dis 133:882-890.
8. Flores-Aguilar M, Besen G, Vuong C, Tatebayashi M, Munguia D, Gangan P, Wiley CA, and Freeman WR (1997). Evaluation of retinal toxicity and efficacy of anti-cytomegalovirus and anti-herpes simplex virus antiviral phosphorothioate oligonucleotides ISIS 2922 and ISIS 4015. J Infect Dis 175:1308-1316.
9. Guvakova MA, Yakubov LA, Vlodavsky I, Tonkinson JL, and Stein CA (1995). Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem 270:2620-2627.
10. Hertl M, Neckers LM, and Katz SI (1995). Inhibition of interferon-gamma-induced intercellular adhesion molecule-1 expression on human keratinocytes by phosphorothioate antisense oligodeoxynucleotides is the consequence of antisense-specific and antisense-non-specific effects. J Invest Dermatol 104:813-818.
11. Krieg AM, Love-Homan L, Yi AK, and Harty JT (1998). CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol 161: 2428-2434.
12. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, and Klinman DM (1995). CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546-549.
13. Lima WF, Monia BP, Ecker DJ, and Freier SM (1992). Implication of RNA structure on antisense oligonucleotide hybridization kinetics. Biochemistry 31:12055-12061.
14. Loke SL, Stein CA, Zhang XH, Mori K, Nakanishi M, Subasinghe C, Cohen JS, and Neckers LM (1989). Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci USA 86:3474-3478.
15. McKay IA and Leigh IM (1995). Altered keratinocyte growth and differentiation in psoriasis. Clin Dermatol 13:105-114.
16. Molhuizen HO, Alkemade HA, Zeeuwen PL, de Jongh GJ, Wieringa B, and Schalkwijk J (1993). SKALP/elafin: An elastase inhibitor from cultured human keratinocytes. Purification, cDNA sequence, and evidence for transglutaminase cross-linking. J Biol Chem 268:12028-12032.
17. Monia BP, Johnston JF, Geiger T, Muller M, and Fabbro D (1996). Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med 2:668-675.
18. Nestle FO, Mitra RS, Bennett CF, Chan H, and Nickoloff BJ (1994). Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes. J Invest Dermatol 103: 569-575.
19. Perez JR, Li Y, Stein CA, Majumder S, van Oorschot A, and Narayanan R (1994). Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oligodeoxynucleotides. Proc Natl Acad Sci USA 91:5957-5961.
20. Schalkwijk J, de Roo C, and de Jongh GJ (1991). Skin-derived antileukoproteinase (SKALP), an elastase inhibitor from human keratinocytes: Purification and biochemical properties. Biochim Biophys Acta 1096:148-154.
21. Schalkwijk J, van Vlijmen IM, Alkemade JA, and de Jongh GJ (1993). Immunohistochemical localization of SKALP/elafin in psoriatic epidermis. J Invest Dermatol 100:390-393.
22. Schwartz DA, Quinn TJ, Thorne PS, Sayeed S, Yi AK, and Krieg AM (1997). CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. J Clin Invest 100:68-73.
23. Sharma HW and Narayanan R (1995). The therapeutic potential of antisense oligonucleotides. Bioessays 17:1055-1063.
24. Smith CH and Barker JN (1995). Cell trafficking and role of adhesion molecules in psoriasis. Clin Dermatol 13:151-160.
25. Smyth AP, Rook SL, Detmar M, and Robinson GS (1997). Antisense oligonucleotides inhibit vascular endothelial growth factor/vascular permeability factor expression in normal human epidermal keratinocytes. J Invest Dermatol 108: 523-526.
26. Stein CA (1995). Does antisense exist? Nat Med 1:1119-1121.
27. van Duijnhoven JL, Schalkwijk J, Kranenborg MH, van Vlijmen-Willems IM, Groeneveld A, van Erp PE, Timmer ED, de Jongh GJ, and van de Ven WJ (1992). MOM-150, a versatile monoclonal antibody against involucrin: Characterization and applications. Arch Dermatol Res 284:167-172.
28. van Ruissen F, van de Kerkhof PC, and Schalkwijk J (1995). Signal transduction pathways in epidermal proliferation and cutaneous inflammation. Clin Dermatol 13:161-190.
29. Wagner RW (1995). The state of the art in antisense research. Nat Med 1:1116-1118.
30. Wiedow O, Harder J, Bartels J, Streit V, and Christophers E (1998). Antileukoprotease in human skin: An antibiotic peptide constitutively produced by keratinocytes. Biochem Biophys Res Commun 248:904-909.
31. Wiedow O, Schroder JM, Gregory H, Young JA, and Christophers E (1990). Elafin: An elastase-specific inhibitor of human skin: Purification, characterization, and complete amino acid sequence. J Biol Chem 265:14791-14795.
32. Wingens M, van Bergen BH, Hiemstra PS, Meis JFGM, van Vlijmen-Willems IMJJ, Zeeuwen PLJM, Mulder J, Kramps HA, van Ruissen F, and Schalkwijk J (1998a). Induction of SLPI (ALP/HUSI-I) in epidermal keratinocytes. J Invest Dermatol 111:101-107.
33. Wingens M, van Hooijdonk CAEM, de Jongh GJ, Schalkwijk J, and van Erp PE (1998b). Flow cytometric and microscopic characterization of the uptake and distribution of phosphorothioate oligonucleotides in human keratinocytes. Arch Dermatol Res 290:119-125.
34. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisner DL, and Shanahan WR Jr (1998). A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 114: 1133-1142.
35. Yakubov LA, Deeva EA, Zarytova VF, Ivanova EM, Ryte AS, Yurchenko LV, and Vlassov W (1989). Mechanism of oligonucleotide uptake by cells: Involvement of specific receptors? Proc Natl Acad Sci USA 86:6454-6458.